Infectious disease
It was recently announced that a low dose of the Pfizer-BioNTech vaccine is safe for kids ages 5 to 11.
IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.
The U.S. Centers for Disease Control and Prevention (CDC) reported that the Omicron variant of COVID-19 had been identified in California.
GlaxoSmithKline said early research shows its monoclonal antibody is demonstrating efficacy against the newest strain of COVID-19.
Research continues to reveal how COVID-19 affects different people with different health issues, both short-term and long-term.
It may take two to four weeks before experts have enough data to know whether Omicron is a bigger threat than Delta. Much of what is known is based on lab tests and models of the virus’ spike protein mutations.
The FDA’s Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of molnupiravir. Read more about the authorization here.
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
PRESS RELEASES